Hepatocellular carcinoma cell surface

Hepatocellular carcinoma (HCC) cell surface refers to the complex landscape of proteins, glycoproteins, and glycolipids expressed on the plasma membrane of malignant hepatocytes. These surface molecules serve as critical mediators of tumor growth, survival, and interaction with the tumor microenvironment (NIH, 2023). Common specific targets within this category include Glypican-3 (GPC3), asialoglycoprotein receptor (ASGPR), and various immune checkpoint ligands like PD-L1 (PubMed, 2022). Therapeutic strategies targeting the HCC cell surface include monoclonal antibodies, antibody-drug conjugates (ADCs), and chimeric antigen receptor (CAR) T-cell therapies (Nature Reviews Gastroenterology & Hepatology, 2021). Because the term describes a cellular location rather than a single molecular entity, it is considered a broad target category rather than a specific therapeutic target (PubChem, 2024). Consequently, drug development efforts focus on identifying specific antigens on this surface that are overexpressed in tumor cells compared to healthy liver tissue to minimize off-target effects (ScienceDirect, 2023).

Other names

HCC cell surface antigensHepatoma cell surface markersHepatocellular carcinoma surface proteins

Targeting of specific surface antigens to inhibit oncogenic signaling, deliver cytotoxic payloads, or enhance immune recognition.